We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

127 hedge funds and large institutions have $323M invested in Atea Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 10

59% more capital invested

Capital invested by funds: $203M → $323M (+$119M)

14% more funds holding

Funds holding: 111 → 127 (+16)

2.47% more ownership

Funds ownership: 72.96% → 75.43% (+2.5%)

3% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 38

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
127
Holders Change
+16
Holders Change %
+14.41%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
27
Increased
39
Reduced
38
Closed
10
Calls
$612K
Puts
–
Net Calls
+$612K
Net Calls Change
+$602K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.4M
2
RA
Rosalind Advisors
Ontario, Canada
+$5.38M
3
Two Sigma Investments
Two Sigma Investments
New York
+$5.14M
4
ICM
Irenic Capital Management
New York
+$1.39M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.28M

Top Sellers

1
BCM
BML Capital Management
Indiana
-$1.98M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.87M
3
Millennium Management
Millennium Management
New York
-$1.6M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$853K
5
PLC
Peapod Lane Capital
New York
-$745K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
26
Opaleye Management
Massachusetts
$1.74M +$656K +142,785 +79%
ICM
27
Irenic Capital Management
New York
$1.62M +$1.39M +301,699 New
PLC
28
Peapod Lane Capital
New York
$1.44M -$745K -162,200 -37%
HSBC Holdings
29
HSBC Holdings
United Kingdom
$1.38M +$81.4K +17,715 +7%
N
30
Nuveen
North Carolina
$1.31M +$11.6K +2,515 +1%
Arrowstreet Capital
31
Arrowstreet Capital
Massachusetts
$1.13M +$967K +210,542 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1,000K -$58.1K -12,658 -6%
AI
33
Auour Investments
Massachusetts
$952K – – –
American Century Companies
34
American Century Companies
Missouri
$900K -$14.2K -3,096 -2%
Barclays
35
Barclays
United Kingdom
$866K -$377K -82,044 -34%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$841K +$607K +132,258 +548%
SEI Investments
37
SEI Investments
Pennsylvania
$841K +$718K +156,384 New
BCM
38
Bridgeway Capital Management
Texas
$798K – – –
Invesco
39
Invesco
Georgia
$717K +$209K +45,442 +52%
Point72 Asset Management
40
Point72 Asset Management
Connecticut
$643K +$256K +55,648 +87%
EI
41
EAM Investors
California
$607K +$518K +112,866 New
UBS Group
42
UBS Group
Switzerland
$592K -$379K -82,590 -43%
T. Rowe Price Associates
43
T. Rowe Price Associates
Maryland
$574K +$42.4K +9,242 +9%
Bank of America
44
Bank of America
North Carolina
$568K -$138K -30,154 -22%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$537K +$39.3K +8,558 +9%
SO
46
STRS Ohio
Ohio
$519K -$78.5K -17,100 -15%
JF
47
Jump Financial
Illinois
$502K +$340K +74,134 +388%
AC
48
Aldebaran Capital
Indiana
$484K -$2.68K -583 -0.6%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$479K -$22.6K -4,922 -5%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$440K +$297K +64,679 +377%
1
2
3 4 5

AVIR Hedge Fund Activity: Q1 2026 in Review

127 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2026, worth a combined $323M — up 59% from $203M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AVIR positions and 10 closed out — a net gain of 17 holders — while 39 added to existing stakes and 38 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $10.4M. The largest seller was BML Capital Management, cutting an estimated $1.98M.

  • 127 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2026, up from 111 in Q4 2025.
  • Funds reported $323M of Atea Pharmaceuticals stock for Q1 2026, up 59% quarter-over-quarter.
  • 27 funds opened new Atea Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
  • The largest Atea Pharmaceuticals buyer in Q1 2026 was Fidelity Investments, an estimated $10.4M added.
  • The largest Atea Pharmaceuticals seller in Q1 2026 was BML Capital Management, an estimated $1.98M sold.

Based on aggregated 13F filings for Q1 2026.